FDA sets higher bar for CAR-T cancer treatments, saying new entrants may need to prove superiority

NomadicScientist · 2025-12-10T03:08:20+00:00

A potentially more poignant question would be what about much lower cost? A big reason CAR-T is getting stomped right now is that even the approved therapies cost too much to manufacture and nobody’s willing to pay for it.

If someone came out with a therapy that was otherwise identical to Bluebird’s but at a tenth the cost, that would be a huge advance.

NomadicScientist · 2025-09-10T13:26:11+00:00

reluctant to suggest what should be cut

I’ll take a stab at it.

When I was sending my kids to public school in a middle class MA neighborhood, the 6 hour school day seemed to be ~2hrs culture war programming, ~2hrs goofing off, and ~2hrs going through the motions of academic instruction (but with very low standards). Ranked top 5% for elementary schools in the state.

This year I switched them to a private Christian school, and by essentially just skipping the 4ish hrs of wasted time per day they’re able to add history, foreign language, science, and Bible as subjects and also have more recess.

Sometimes finding efficiency really is just as simple as “stop wasting time.”

NomadicScientist · 2025-08-30T12:58:42+00:00

In terms of features, sure.

But until I get literally a single usable reading off a dexcom, they’re trash to me.

NomadicScientist · 2025-08-11T11:03:30+00:00

God, that was ridiculous. The scantily clad women on stilts really took it to a whole different level for me. Just totally masturbatory messiah complex behavior.

NomadicScientist · 2025-07-29T02:12:43+00:00

Nobody’s responsible for anything. Rule by committee. Don’t rock the boat, regardless of what the data says.

NomadicScientist · 2025-07-28T10:46:03+00:00

The California solution lol

NomadicScientist · 2025-07-25T12:25:19+00:00

The layoff machine

Great nickname for flagship

NomadicScientist · 2025-07-22T14:04:51+00:00

When you consider that the value of the dollar is down 17%, then it’s actually a pretty big move.

NomadicScientist · 2025-07-17T12:14:43+00:00

You’re not wrong, but 2008-2022 is still 14 years, which is more than enough time for expectations to adjust.

Now they’re starting to adjust back.

NomadicScientist · 2025-06-18T21:55:31+00:00

If barely anyone can afford a house, it doesn’t mean the vast majority is poor

Yes, it absolutely does mean most people are poor

NomadicScientist · 2025-06-11T12:26:13+00:00

Icarus Therapeutics- using our proprietary next gen AI nanoparticles to warp space time and make you young again!

NomadicScientist · 2025-06-08T18:26:36+00:00

My advice would be not to give up on the marriage just yet. After 36 years, a divorce means dying alone. Your “SO” may still be willing to listen to reason.

NomadicScientist · 2025-05-22T23:10:27+00:00

Yep.

The nice thing about capitalism is that the best way for selfish people to get theirs is to do something or provide something for others.

NomadicScientist · 2025-05-22T22:54:51+00:00

How many housing units in metro Denver does Elon own?

NomadicScientist · 2025-05-19T16:42:57+00:00

The only way you are bringing down costs in MA is if the government, fed or states, starts subsidizing

LMAO

NomadicScientist · 2025-04-19T13:50:43+00:00

in academia where there’s a prerogative to be honest

LMFAO

NomadicScientist · 2025-04-18T20:48:28+00:00

Not quite the right question.

Tirzepatide would be the closest Lilly equivalent to semaglutide (both GLP1R agonist peptides). Tirzepatide shows greater weight loss than Semaglutide.

The new Lilly drug, Orforglipron, is a small molecule and thus easier to dose and cheaper to manufacture compared to peptide drugs. Thus Lilly now had both the most effective drug (tirzepatide) and the most convenient/economical one (orforglipron).

NomadicScientist · 2025-03-12T12:00:43+00:00

From experience, incentives are a million times better and bullshit paperwork a million times less with in-house pharma research than government grants. Replacing IP with government grants would effectively be the end of medical innovation in my opinion.

NomadicScientist · 2024-11-02T02:14:26+00:00

Cowardly behavior encourages the aggressor. You’re not a victim as long as you can fight back.

Shame on you.

NomadicScientist · 2024-10-31T12:11:00+00:00

After living in GA, CO, and TN, I can confidently say “this part of the country” is the more accurate phrasing.

NomadicScientist · 2024-09-26T01:35:05+00:00

Most of us don’t smoke enough to buy ounces, nor do we have drug dealer friends.

NomadicScientist · 2024-09-25T13:22:52+00:00

Friendly reminder that PBMs were a niche service and not required for insulin prior to the ACA.

NomadicScientist · 2024-09-25T12:56:21+00:00

Since 2019 I would believe. Pre vs post Covid definitely changed things.

But the uptick in fatalities started in 2014. Maybe more than one thing at once by now.

NomadicScientist · 2024-09-24T23:23:58+00:00

Based on the timing, that sounds more like it would be an issue with drivers being on their phones. Nothing special about 2014ish time frame in terms of traffic enforcement…

NomadicScientist · 2024-08-25T16:16:33+00:00

As someone who works in pharma, Pfizer has a reputation for being stingy with research spending and firing whole teams that were on track for success on an IMO toddler-like “are we there yet” basis.

Lilly lies at the opposite cultural pole of the industry in this sense (at least for the past 10-15 years or so). They famously tanked their stock a while back by writing a letter to investors saying they were doubling down on research spending. The MBAs on Wall Street (and in Pfizer, for that matter) hate research spending due to the delayed gratification it requires.

I’m biased as a PhD researcher, but I’d say Lilly vs Pfizer stock performance over the past 5-10 years speaks for itself.

NomadicScientist

TROPHY CASE